Faeth Therapeutics (FTH) Total Non-Current Liabilities (2020 - 2026)

Faeth Therapeutics (FTH) has reported Total Non-Current Liabilities for 7 consecutive years, with $9.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities changed N/A year-over-year to $9.6 million; the trailing twelve-month figure through Jun 2026 stood at $9.6 million (changed N/A YoY), and the FY2025 full-year result was $4.3 million, changed N/A from the prior year.
• Total Non-Current Liabilities retreated to $9.6 million in Q2 2026 per FTH's latest filing, from $14.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $15.0 million in Q4 2022 and bottomed at $4.3 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $10.2 million across 5 years, with a median of $9.9 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities jumped 128.07% in 2022, then tumbled 37.52% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $15.0 million in 2022, then sank by 37.12% to $9.4 million in 2023, then retreated by 19.89% to $7.5 million in 2024, then slumped by 42.84% to $4.3 million in 2025, then surged by 122.27% to $9.6 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $9.6 million, $14.2 million, and $4.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.